Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. (19th October 2018)

• Record Type: Journal Article
• Authors: Hochmair, Maximilian J; Morabito, Alessandro; Hao, Desiree; Yang, Cheng-Ta; Soo, Ross A; Yang, James C-H; Gucalp, Rasim; Halmos, Balazs; Wang, Lara; Golembesky, Amanda; Märten, Angela; Cufer, Tanja
• Is Part Of: Future oncology. Volume 14:Number 27(2018)
• Page Start: 2861
• Page End: 2874
• Publication Date: 2018-10-19
• Subjects: afatinib -- osimertinib -- NSCLC -- sequential -- T790M; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0711
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting.Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment.Results: Overall median time on treatment was 27.6 months (90% CI: 25.9–31.3), 30.3 months (90% CI: 27.6–44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8–not reached) in Asians. The 2-year overall survival was 78.9%.Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770